Metraipolis › archive › dc_c2bf82611079

Cost-effectiveness analysis of pharmacogenetic-guided antiseizure medication therapy based on the risk of HLA-A*31:01 allele variants in Japan — Europe PMC PMID:41282954

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41282954
DOI
10.1002/pcn5.70249
License (as archived)
solo-consultazione
Archived
2026-11-08T09:32:37.902Z
SHA-256 of the archived text
019477a04c05c0106cfe43c166199df604a7f049a0c5e8ead74ab507bd251bb5
Stable URL of this page
https://metraipolis.com/documento/dc_c2bf82611079

How to cite

Cost-effectiveness analysis of pharmacogenetic-guided antiseizure medication therapy based on the risk of HLA-A*31:01 allele variants in Japan — Europe PMC PMID:41282954 — Europe PMC (en), https://europepmc.org/article/MED/41282954 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c2bf82611079 (Metraipolis archive dc_c2bf82611079, sha256 019477a04c05c0106cfe43c166199df604a7f049a0c5e8ead74ab507bd251bb5)
BibTeX
@misc{dcc2bf82611079,
  title = {Cost-effectiveness analysis of pharmacogenetic-guided antiseizure medication therapy based on the risk of HLA-A*31:01 allele variants in Japan — Europe PMC PMID:41282954},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41282954},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c2bf82611079; sha256 019477a04c05c0106cfe43c166199df604a7f049a0c5e8ead74ab507bd251bb5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41282954. Agents can read the archived copy with the MCP tool read_document.